Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II UM171-expanded cord blood transplantation in high-risk acute leukemia/myelodysplasia
2022-002458-26Phase 2Active
- Sponsor
- ExCellThera
- Start
- Nov 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorocubicel in leukemia, myelodysplastic syndrome (MDS) and None, sponsored by ExCellThera. Primary endpoints: Relapse-free survival at 1 year post-transplant and Relapse-free survival at 2 years post-transplant. Started Nov 2022; status: active.
02
Drugs
dorocubicel
03
Conditions
leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-002458-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002458-26.